Barrington Research Raises Bioventus (NYSE:BVS) Price Target to $14.00

Bioventus (NYSE:BVS) had its price target hoisted by Barrington Research from $13.00 to $14.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Barrington Research’s target price indicates a potential upside of 66.47% from the stock’s current price.

Separately, Craig Hallum raised their price objective on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Bioventus has an average rating of “Buy” and an average target price of $14.25.

Bioventus Stock Down 7.6%

BVS opened at $8.41 on Friday. The company has a market capitalization of $696.04 million, a PE ratio of -13.79 and a beta of 0.78. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $11.25. The business has a 50-day moving average of $8.12 and a 200-day moving average of $7.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BVS. Caitong International Asset Management Co. Ltd raised its stake in shares of Bioventus by 17,156.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares in the last quarter. Anderson Financial Strategies LLC boosted its position in Bioventus by 58.3% during the fourth quarter. Anderson Financial Strategies LLC now owns 213,208 shares of the company’s stock worth $1,586,000 after purchasing an additional 78,488 shares during the period. Invesco Ltd. grew its holdings in Bioventus by 52.9% during the fourth quarter. Invesco Ltd. now owns 33,621 shares of the company’s stock valued at $250,000 after purchasing an additional 11,639 shares during the last quarter. Corient Private Wealth LLC raised its position in shares of Bioventus by 44.9% in the fourth quarter. Corient Private Wealth LLC now owns 19,471 shares of the company’s stock valued at $145,000 after purchasing an additional 6,031 shares during the period. Finally, Mercer Global Advisors Inc. ADV raised its position in shares of Bioventus by 16.2% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after purchasing an additional 1,887 shares during the period. Institutional investors and hedge funds own 62.94% of the company’s stock.

Key Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Solid Q4 results: revenue of $157.9M (+2.8%) with organic growth of 10%, GAAP EPS $0.21 (vs $0.00 prior year), non‑GAAP EPS $0.24, and cash from operations of $38.0M (up 97%). Management said 2026 guidance reflects continued above‑market revenue growth. Globe Newswire Release
• Positive Sentiment: FY‑2026 guidance modestly ahead of consensus on EPS (0.73–0.77 vs. consensus ~0.72) and revenue guidance of $600–$610M (around consensus). The outlook supports improved earnings and cash generation for the year. Guidance Details
• Positive Sentiment: Management set a $600M–$610M 2026 sales target and said it will accelerate investment in high‑growth areas (PNS, PRP, ultrasonics), signaling reinvestment to fuel medium‑term growth. Seeking Alpha
• Positive Sentiment: Analyst upgrades/price target raises: Craig Hallum raised its PT to $16 (buy) and Barrington Research raised its PT to $14 (outperform), both signaling increased analyst confidence and sizable upside from current levels. Benzinga Street Insider
• Positive Sentiment: Market reaction to the print: shares reacted positively to the beat/guidance when markets first digested the news (shares jumped around the release). This confirms the Q4 beat was meaningful to investors. Investing.com
• Neutral Sentiment: Earnings call materials and full transcript are available for deeper review of commentary around product trends, margin drivers and investment cadence — useful for due diligence but not new company-level catalysts by themselves. Yahoo Transcript Seeking Alpha Presentation
• Negative Sentiment: Despite the largely positive fundamentals and analyst upgrades, the stock is trading lower today — likely due to profit‑taking after the early rally, and because 2026 revenue guidance sits roughly in line with street expectations (limiting an outsized upside surprise). This short‑term selling pressure can mask the longer‑term improvements highlighted above.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.